Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Joseph P Sanderson, Darragh J Crowley, Guy E Wiedermann, Laura L Quinn, Katherine L Crossland, Helen M Tunbridge, Terri V Cornforth, Christopher S Barnes, Tina Ahmed, Karen Howe, Manoj Saini, Rachel J Abbott, Victoria E Anderson, Barbara Tavano, Miguel Maroto & Andrew B Gerry. (2020) Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. OncoImmunology 9:1.
Read now
Read now
Devin B. Lowe, Camille K. Bivens, Alexis S. Mobley, Christian E. Herrera, Amanda L. McCormick, Timea Wichner, Manoj K. Sabnani, Laurence M. Wood & Jon A. Weidanz. (2017) TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. mAbs 9:4, pages 603-614.
Read now
Read now
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Read now
Articles from other publishers (38)
Milena Kalaitsidou, Owen R. Moon, Martina Sykorova, Leyuan Bao, Yun Qu, Sujita Sukumaran, Michael Valentine, Xingliang Zhou, Veethika Pandey, Kay Foos, Sergey Medvedev, Daniel J. Powell Jr, Akshata Udyavar, Eric Gschweng, Ruben Rodriguez, Mark E. Dudley, Robert E. Hawkins, Gray Kueberuwa & John S. Bridgeman. (2023) Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes. Frontiers in Immunology 14.
Crossref
Crossref
Adam S. Chervin, Jennifer D. Stone, Iwona Konieczna, Kelly M. Calabrese, Ningyan Wang, Dipica Haribhai, Feng Dong, Michael K. White, Luis E. Rodriguez, Gail T. Bukofzer, Paul A. Ellis, Cormac Cosgrove, Claudie Hecquet, Jerry D. Clarin, Joann P. Palma & Edward B. Reilly. (2023) ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies. Molecular Cancer Therapeutics 22:8, pages 903-912.
Crossref
Crossref
David M. Berman & John I. Bell. (2023) Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors. Clinical Cancer Research 29:4, pages 697-704.
Crossref
Crossref
Srona Sengupta, Nathan L. Board, Fengting Wu, Milica Moskovljevic, Jacqueline Douglass, Josephine Zhang, Bruce R. Reinhold, Jonathan Duke-Cohan, Jeanna Yu, Madison C. Reed, Yasmine Tabdili, Aitana Azurmendi, Emily J. Fray, Hao Zhang, Emily Han-Chung Hsiue, Katharine Jenike, Ya-Chi Ho, Sandra B. Gabelli, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou, Janet D. Siliciano, Scheherazade Sadegh-Nasseri, Ellis L. Reinherz & Robert F. Siliciano. (2022) TCR-mimic bispecific antibodies to target the HIV-1 reservoir. Proceedings of the National Academy of Sciences 119:15.
Crossref
Crossref
Lei Cui, Feng Yin, Jingbo Cheng, Hui Liu, Meimei Zheng, Di Liu, Zeji Wu & Qiqun Qian. (2021) Optimized cytotoxicity assay for co-suspended effector and target cells. Journal of Immunological Methods 497, pages 113100.
Crossref
Crossref
Dan You, Stephen Hillerman, Gregory Locke, Charu Chaudhry, Caitlyn Stromko, Anwar Murtaza, Yi Fan, Jennifer Koenitzer, Yali Chen, Stephanie Briceno, Rajarshi Bhadra, Elizabeth Duperret, Johnni Gullo-Brown, Chan Gao, Dandan Zhao, John Feder, Joshua Curtin, Andrew P Degnan, Godwin Kumi, Mark Wittman, Benjamin M Johnson, Karen E Parrish, Giridharan Gokulrangan, John Morrison, Michael Quigley, John T Hunt, Luisa Salter-Cid, Emma Lees, Miguel A Sanjuan & Jinqi Liu. (2021) Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor. Journal for ImmunoTherapy of Cancer 9:1, pages e001402.
Crossref
Crossref
Chi-Xiao Qiu, Xue-Fei Bai, Ying Shen, Zhan Zhou, Li-Qiang Pan, Ying-Chun Xu, Wen-Bin Zhao & Shu-Qing Chen. (2020) Specific Inhibition of Tumor Growth by T Cell Receptor–Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1. Bioconjugate Chemistry 31:12, pages 2767-2778.
Crossref
Crossref
Qi Liu, Ye Tian, Yanyan Li, Wei Zhang, Wenxuan Cai, Yaju Liu, Yuefei Ren, Zhaoduan Liang, Peipei Zhou, Yajing Zhang, Yifeng Bao & Yi Li. (2020) In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 8:2, pages e001748.
Crossref
Crossref
Guozhu Xie, Nikola A. Ivica, Bin Jia, Yingzhong Li, Han Dong, Yong Liang, Douglas Brown, Rizwan Romee & Jianzhu Chen. (2020) CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nature Biomedical Engineering 5:5, pages 399-413.
Crossref
Crossref
Han Xu, Agnes E. Hamburger, Jee-Young Mock, Xueyin Wang, Aaron D. Martin, Talar Tokatlian, Julyun Oh, Mark E. Daris, Kathleen R. Negri, Grant B. Gabrelow, Ming Lun Wu, Daniel P. Nampe, Grace E. Asuelime, Michele E. McElvain, Mark L. Sandberg & Alexander Kamb. (2020) Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen. Molecular Immunology 126, pages 56-64.
Crossref
Crossref
Sneha Sant, Sergio M. Quiñones-Parra, Marios Koutsakos, Emma J. Grant, Thomas Loudovaris, Stuart I. Mannering, Jane Crowe, Carolien E. van de Sandt, Guus F. Rimmelzwaan, Jamie Rossjohn, Stephanie Gras, Liyen Loh, Thi H. O. Nguyen & Katherine Kedzierska. (2020) HLA-B*27:05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells. PLOS Pathogens 16:8, pages e1008714.
Crossref
Crossref
Diana Campillo-Davo, Donovan Flumens & Eva Lion. (2020) The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses. Cells 9:7, pages 1720.
Crossref
Crossref
Meagan R. Rollins, Ellen J. Spartz & Ingunn M. Stromnes. (2020) T Cell Receptor Engineered Lymphocytes for Cancer Therapy. Current Protocols in Immunology 129:1.
Crossref
Crossref
Lun Cai, Leidy D. Caraballo Galva, Yibing Peng, Xiaobing Luo, Wei Zhu, Yihong Yao, Yun Ji & Yukai He. (2020) Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells. Frontiers in Immunology 11.
Crossref
Crossref
Hans-Peter Gerber, Leah V. Sibener, Luke J. Lee & Marvin H. Gee. (2020) Identification of Antigenic Targets. Trends in Cancer 6:4, pages 299-318.
Crossref
Crossref
Diana Campillo-Davo, Maarten Versteven, Gils Roex, Hans De Reu, Sanne van der Heijden, Sébastien Anguille, Zwi N. Berneman, Viggo F. I. Van Tendeloo & Eva Lion. (2020) Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. Cancers 12:2, pages 256.
Crossref
Crossref
N. Tsur, Y. Kogan, M. Rehm & Z. Agur. (2020) Response of patients with melanoma to immune checkpoint blockade – insights gleaned from analysis of a new mathematical mechanistic model. Journal of Theoretical Biology 485, pages 110033.
Crossref
Crossref
Neta Tsur, Yuri Kogan, Evgenia Avizov-Khodak, Désirée Vaeth, Nils Vogler, Jochen Utikal, Michal Lotem & Zvia Agur. (2019) Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. Journal of Translational Medicine 17:1.
Crossref
Crossref
Hans-Peter Gerber, Leah V. Sibener, Luke J. Lee & Marvin Gee. (2019) Intracellular targets as source for cleaner targets for the treatment of solid tumors. Biochemical Pharmacology 168, pages 275-284.
Crossref
Crossref
Bertil E. Damato, Joseph Dukes, Howard Goodall & Richard D. Carvajal. (2019) Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers 11:7, pages 971.
Crossref
Crossref
Andreas Moritz, Raghavendra Anjanappa, Claudia Wagner, Sebastian BunkMartin Hofmann, Gabriele PszollaAnkur Saikia, Maria Garcia-AlaiRob Meijers, Hans-Georg Rammensee, Sebastian Springer & Dominik Maurer. (2019) High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules. Science Immunology 4:37.
Crossref
Crossref
Kate L. Lowe, David Cole, Rupert Kenefeck, Ita OKelly, Marco Lepore & Bent K. Jakobsen. (2019) Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treatment Reviews 77, pages 35-43.
Crossref
Crossref
Ellen K. Wagner, Ahlam N. Qerqez, Christopher A. Stevens, Annalee W. Nguyen, George Delidakis & Jennifer A. Maynard. (2019) Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display. Journal of Biological Chemistry 294:15, pages 5790-5804.
Crossref
Crossref
Hongbing Yang, Zoë Wallace & Lucy Dorrell. (2018) Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction. Frontiers in Immunology 9.
Crossref
Crossref
Jane Harper, Katherine J. Adams, Giovanna Bossi, Debbie E. Wright, Andrea R. Stacey, Nicole Bedke, Ruth Martinez-Hague, Dan Blat, Laure Humbert, Hazel Buchanan, Gabrielle S. Le Provost, Zoe Donnellan, Ricardo J. Carreira, Samantha J. Paston, Luise U. Weigand, Martina Canestraro, Joseph P. Sanderson, Sophie Botta Gordon-Smith, Kate L. Lowe, Karolina A. Rygiel, Alex S. Powlesland, Annelise Vuidepot, Namir J. Hassan, Brian J. Cameron, Bent K. Jakobsen & Joseph Dukes. (2018) An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLOS ONE 13:10, pages e0205491.
Crossref
Crossref
Yuan Chen, Shao-An Xue, Shahriar Behboudi, Goran H. Mohammad, Stephen P. Pereira & Emma C. Morris. (2017)
Ex Vivo
PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients
. Clinical Cancer Research 23:20, pages 6178-6189.
Crossref
Crossref
Maurizio Zanetti. (2016) A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology 14:2, pages 115-128.
Crossref
Crossref
Victoria Hillerdal, Vanessa F. Boura, Hanna Björkelund, Karl Andersson & Magnus Essand. (2016) Avidity characterization of genetically engineered T-cells with novel and established approaches. BMC Immunology 17:1.
Crossref
Crossref
Hongbing Yang, Sandrine Buisson, Giovanna Bossi, Zoë Wallace, Gemma Hancock, Chun So, Rebecca Ashfield, Annelise Vuidepot, Tara Mahon, Peter Molloy, Joanne Oates, Samantha J Paston, Milos Aleksic, Namir J Hassan, Bent K Jakobsen & Lucy Dorrell. (2016) Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors. Molecular Therapy 24:11, pages 1913-1925.
Crossref
Crossref
Emma S. Hickman, Martine E. Lomax & Bent K. Jakobsen. (2016) Antigen Selection for Enhanced Affinity T-Cell Receptor–Based Cancer Therapies. SLAS Discovery 21:8, pages 769-785.
Crossref
Crossref
Young-Hee Kim, Thi-Anh-Thuy Tran, Hyun-Ju Lee, Sook-In Jung, Je-Jung Lee, Wool-Youl Jang, Kyung-Sub Moon, In-Young Kim, Shin Jung & Tae-Young Jung. (2016) Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99. Oncotarget 7:31, pages 50535-50547.
Crossref
Crossref
Anthony W Purcell, Nathan P Croft & David C Tscharke. (2016) Immunology by numbers: quantitation of antigen presentation completes the quantitative milieu of systems immunology!. Current Opinion in Immunology 40, pages 88-95.
Crossref
Crossref
J.A. ATZIN-MÉNDEZ, J.S. LÓPEZ-GONZÁLEZ, R. BÁEZ, M.C. ARENAS-DEL ANGEL, L.F. MONTAÑO, D. SILVA-ADAYA, R. LASCURAIN & P. GOROCICA. (2016) Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes. Oncology Reports 35:1, pages 33-42.
Crossref
Crossref
Christopher C Kloss & Marcela V Maus. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
9
.
Joanne Oates, Namir J. Hassan & Bent K. Jakobsen. (2015) ImmTACs for targeted cancer therapy: Why, what, how, and which. Molecular Immunology 67:2, pages 67-74.
Crossref
Crossref
Geir Åge Løset, Gøril Berntzen, Terje Frigstad, Sylvie Pollmann, Kristin S. Gunnarsen & Inger Sandlie. (2015) Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide–MHC Interactions. Frontiers in Oncology 4.
Crossref
Crossref
Tomohide Tsukahara, Makoto Emori, Kenji Murata, Takahisa Hirano, Norihiro Muroi, Masanori Kyono, Shingo Toji, Kazue Watanabe, Toshihiko Torigoe, Vitaly Kochin, Hiroko Asanuma, Hiroshi Matsumiya, Keiji Yamashita, Tetsuo Himi, Shingo Ichimiya, Takuro Wada, Toshihiko Yamashita, Tadashi Hasegawa & Noriyuki Sato. (2014) Specific Targeting of a Naturally Presented Osteosarcoma Antigen, Papillomavirus Binding Factor Peptide, Using an Artificial Monoclonal Antibody. Journal of Biological Chemistry 289:32, pages 22035-22047.
Crossref
Crossref
Giovanna Bossi, Sandrine Buisson, Joanne Oates, Bent K. Jakobsen & Namir J. Hassan. (2014) ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunology, Immunotherapy 63:5, pages 437-448.
Crossref
Crossref